Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib. Issue 11 (2nd November 2022)

• Record Type: Journal Article
• Authors: Wassermann, Johanna; Bagnis, Corinne Isnard; Leenhardt, Laurence; Ederhy, Stéphane; Buffet, Camille
• Is Part Of: Expert opinion on drug safety. Volume 21:Issue 11(2022)
• Page Start: 1401
• Page End: 1410
• Publication Date: 2022-11-02
• Subjects: Antiangiogenic treatment -- hypertension -- lenvatinib -- proteinuria -- radioiodine-refractory thyroid cancer -- toxicities -- renal -- cardiovascular -- tyrosine kinase inhibitors; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2022.2153115
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: Multi-receptor tyrosine kinase inhibitors with anti-angiogenic activity, particularly lenvatinib, have become the standard treatment for radioiodine-refractory metastatic differentiated thyroid cancer but are associated with a high incidence of toxicity. Although patients treated with lenvatinib have been shown to have a significant improvement in progression-free survival, lenvatinib-associated toxicity may result in dose reductions, dose interruptions or even complete lenvatinib withdrawal, compromising anti-tumor efficacy. Areas covered: The article covers the main cardiological and renal toxicities of lenvatinib, including hypertension, prolonged QT interval, heart failure, arterial and venous thromboembolic events, proteinuria and renal failure, and proposes appropriate management of these events during lenvatinib therapy. We performed a literature review of cardiovascular and renal toxicities of Lenvatinib in radioiodine-refractory differentiated thyroid cancer. We discussed prophylactic and therapeutic management for each toxicity based on literature and clinical expertise. Expert opinion: Specific pre-therapeutic evaluation and close monitoring of patients treated with lenvatinib is necessary to prevent and detect cardiovascular and/or renal toxicities early, and to propose appropriate management. Oncologists who treat patients with lenvatinib should know how to monitor and treat these adverse events, and when to ask for the advice of a specialist (cardiologist or nephrologist).